POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride provides potassium ions for maintenance of electrolyte balance; dextrose provides caloric support; sodium chloride maintains extracellular fluid osmolarity.
| Metabolism | Potassium and sodium are not metabolized; dextrose is metabolized via glycolysis and oxidative phosphorylation. |
| Excretion | Primarily renal (90% as potassium ions), with minor fecal (10%) and negligible biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 2-4 hours for potassium ions, reflecting rapid renal clearance but can be prolonged in renal impairment. |
| Protein binding | Minimal; potassium ions do not bind significantly to plasma proteins (<1%). |
| Volume of Distribution | Total body water distribution, approximately 0.5-0.6 L/kg, reflecting intracellular (98%) and extracellular (2%) compartments. |
| Bioavailability | Oral: 90-100% (immediate-release formulations); intravenous: 100% (direct bioavailability). |
| Onset of Action | Intravenous: immediate (within seconds to minutes) upon administration; oral: 30-60 minutes after absorption. |
| Duration of Action | Intravenous: 2-4 hours for electrolyte correction; oral: 4-6 hours for sustained potassium repletion. |
| Molecular Weight | 74.55 |
Intravenous infusion; rate and volume determined by electrolyte needs and fluid status; typical maintenance: 0.9% sodium chloride with 20 mEq/L potassium chloride at 125 mL/hour; potassium chloride 0.3% provides 40 mEq/L, dextrose 5% and sodium chloride 0.11% provides 19 mEq/L sodium; consult institutional protocols.
| Dosage form | INJECTABLE |
| Renal impairment | GFR >50 mL/min: no adjustment; GFR 30-50 mL/min: reduce potassium infusion rate by 50% and monitor serum potassium; GFR <30 mL/min: avoid potassium administration unless severe deficiency with close monitoring; use with caution in oliguria. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: monitor potassium levels closely; Child-Pugh C: use with caution, reduce infusion rate by 25-50% and monitor for hyperkalemia. |
| Pediatric use | Weight-based: 0.5-1 mEq/kg/day of potassium, maximum infusion rate 0.5-1 mEq/kg/hour; administer as continuous infusion; typical solution: 20-40 mEq/L potassium in compatible IV fluid; adjust based on serum potassium and clinical status. |
| Geriatric use | Reduce initial infusion rate by 25-50% due to age-related decline in renal function; monitor serum potassium and renal function frequently; avoid rapid infusion; consider lower potassium concentration (20 mEq/L) initially. |
| 1st trimester | Potassium chloride and dextrose/sodium chloride solutions are generally considered safe when used as indicated. However, caution is advised in hyperemesis gravidarum or conditions requiring electrolyte correction. No known teratogenicity. |
| 2nd trimester | Similar to first trimester; use is safe when indicated for electrolyte replacement or maintenance. Monitor serum potassium and glucose. |
| 3rd trimester | Safe when used appropriately. High doses may cause maternal hyperkalemia or fluid overload, which could affect the fetus. Avoid in preeclampsia with pulmonary edema. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium, sodium, chloride, and glucose readily cross the placenta. Transfer is passive and concentration-dependent. Fetal serum levels mirror maternal levels with a slight lag. |
| Breastfeeding | Potassium, chloride, dextrose, and sodium are normal constituents of breast milk. Administration to the mother does not pose a risk to the infant. However, monitor for potential hyperkalemia or hyperglycemia in the mother, which could indirectly affect the infant. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | No known teratogenic risk; potassium chloride, dextrose, and sodium chloride are physiological electrolytes and nutrients. No specific trimester risks identified at standard doses. However, maternal hyperkalemia or hypoglycemia may indirectly affect fetal outcome. |
| Fetal Monitoring | Monitor maternal serum electrolytes (potassium, sodium, glucose), fluid balance, and renal function. Fetal heart rate monitoring if clinically indicated (e.g., for maternal metabolic disturbances). |
| Fertility Effects | No known effects on fertility; these are physiological components and do not alter reproductive function. |
■ FDA Black Box Warning
No FDA black box warning for this combination product.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaRenal failure with oliguria or anuriaSevere metabolic acidosis with hyperkalemiaClinically significant hyperglycemia not controlled by insulin (for dextrose component)
| Precautions | Monitor serum potassium to avoid hyperkalemia, Use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia, Check for signs of fluid overload or electrolyte disturbances, Do not administer concentrated potassium solutions; must be diluted |
| Food/Dietary | This is an intravenous solution; no oral dietary interactions. However, oral dietary potassium and sodium intake should be considered when planning total electrolyte replacement. Patients on low-potassium or low-sodium diets should notify their healthcare provider. |
| Clinical Pearls | This solution is a hypotonic maintenance fluid providing potassium for replacement. Use with caution in renal impairment, as hyperkalemia may develop rapidly. Administer via central line if concentration > 2.5% mEq/mL (this is 0.3% KCl = 4 mEq/100 mL, so peripheral administration is safe). Monitor serum potassium and glucose levels, especially in diabetic patients. Do not infuse with blood products. Incompatible with amphotericin B, diazepam, and phenytoin. Check for IV compatibilities before co-administration. |
| Patient Advice | This intravenous fluid contains potassium, dextrose (sugar), and sodium chloride (salt). · Tell your healthcare provider if you have kidney problems, diabetes, or are on a low-potassium or low-salt diet. · Report any pain, redness, swelling, or burning at the IV site immediately. · You may experience increased urination as the fluid is administered. · Do not adjust the IV drip rate yourself; it is controlled by the healthcare team. · Inform your doctor if you have symptoms of high potassium (muscle weakness, numbness, tingling, irregular heartbeat) or high blood sugar (increased thirst, frequent urination, fruity breath). |
Loading safety data…